Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 4/20 | 0.35 |
| ▸ | MMP10 | P09238 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PTAFR | P25105 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871627 | 0.87 | MAPT (0.40) | LIPGL3MBTL1KMT2ATHRBPTAFR | |
| SCHEMBL5871823 | 0.82 | MAPT (0.42) | L3MBTL1MEN1KMT2ANPBWR1THRB | |
| SCHEMBL5871987 | 0.82 | MAPT (0.48) | L3MBTL1THRB | |
| SCHEMBL5872271 | 0.74 | MAPT (0.41) | L3MBTL1MEN1KMT2ANPBWR1THRB | |
| SCHEMBL7954712 | 0.63 | PDE4A (0.48) | L3MBTL1MEN1KMT2ATHRB | |
| SCHEMBL5871439 | 0.62 | LIPG (0.43) | LIPGL3MBTL1MEN1KMT2ATHRB | |
| SCHEMBL7955057 | 0.61 | PDE4A (0.51) | MEN1KMT2ATHRB | |
| SCHEMBL7954380 | 0.60 | RXFP1 (0.52) | SMN1; SMN2HSD17B10MEN1KMT2ATHRB | |
| SCHEMBL9709087 | 0.60 | KMT2A (0.50) | LIPGL3MBTL1KMT2ATHRB | |
| SCHEMBL28966880 | 0.59 | ADORA2A (0.43) | HPGDNPBWR1FEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | claimed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | claimed |
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | LIPG 3691/4885L3MBTL1 1727/4885SMN1; SMN2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.